問題 › 取引獲得のため値引きを続けている › ヘルステック・デジタルヘルス
日常的な値引きは通常、証明の問題とインセンティブの問題であり、リスト価格の問題であることはほとんどありません。 デジタルヘルス企業にとってこれが難しい理由は構造的です。成果リスクを負担できるかどうかを企業が確認できる前に契約が進み、測定期間12ヶ月に対し営業サイクル11ヶ月というずれが生じます。したがって有効な対応は、収益シェアとエンゲージメント率を同時に扱う必要がありますが、両者が別システムにあるため社内分析がここで止まります。
日常的な値引きは通常、証明の問題とインセンティブの問題であり、リスト価格の問題であることはほとんどありません。 デジタルヘルス企業にとってこれが難しい理由は構造的です。成果リスクを負担できるかどうかを企業が確認できる前に契約が進み、測定期間12ヶ月に対し営業サイクル11ヶ月というずれが生じます。したがって有効な対応は、収益シェアとエンゲージメント率を同時に扱う必要がありますが、両者が別システムにあるため社内分析がここで止まります。
成果連動収益シェアが成約の常套手段になると、契約上のシェアは値引き後の水準に固定され、提示価格は飾りになります。これによる損失は粗利を超えます。支払者や提供者に対し、企業が実際に受け入れる水準を明示してしまうため、期待を巻き戻すには時間がかかります。
要因は測定期間に起因します。営業サイクル11ヶ月では12ヶ月を要する成果を示せないため、価格が残された変数になります。また報酬がロゴ獲得や登録数で決まり、成果シェアの粗利が考慮されません。あるいはPMPM譲歩の承認権限が各担当者にあり、行使されるためです。
診断は数値のパターンにあります。類似のエンゲージメント率であるにもかかわらず、深い成果連動シェアや低いPMPM条件が特定の四半期や特定の担当者に集中する場合、原因は成果の経済性ではなくインセンティブと権限にあります。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ 四半期末の最終週に成果連動シェアやPMPM譲歩が急増する
✓ 同等のエンゲージメント率・ロゴプロファイルの取引で、担当者ごとに合意した成果連動シェアやPMPM条件に大きなばらつきがある
✓ 営業が成果の追加証明ではなく、成果連動シェアの譲歩権限拡大を求める
通常、事態を悪化させる対応です。 最近の成約に合わせて基本PMPMを引き下げ、新たな基準値を作り、次の2四半期以内に同等の譲歩を再び引き起こすことです。
It is for you if you run or finance a digital health company and discounts spike at period end. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Pricing & Revenue Optimization, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
裁量に上限を設け、収益ではなく粗利で報酬を支払います。値引きは、収益で測られるノルマと無制限の価格権限に対する合理的な反応です。
いいえ。期間、量、またはリファレンスといった欲しいものと deliberate に交換する場合です。交渉終盤の反射的な値引きは、何も得ずに粗利を失う行為です。
更新時に通知と理由を添えて条件を変更し、一部離脱を受け入れます。代替策は市場の残りがやがて知る恒常的な二重価格です。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית